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A characteristic pathological feature of malignant glio-
ma cells is their ability to extensively invade surrounding
brain parenchyma–particularly along white matter tracts–
thus rendering focal therapies incapable of controlling tu-
mor growth and resulting in inevitable recurrence. In this
regard, identification of factors responsible for such inva-
sion has become a central theme in glioma research, and
elucidation of intracellular signal transduction systems
and regulatory mechanisms important for controlling the
process of invasion are of great clinical interest.
In the article by Kubiatowski, et al., in this issue (Ku-
biatowski T, Jang T, Lachyankar MB, et al: Association of
increased phosphatidylinositol 3-kinase signaling with in-
creased invasiveness and gelatinase activity in malignant
gliomas. J Neurosurg 95:480–488, September, 2001), the
authors have demonstrated that increased phosphati-
dylinositol 3-kinase (PI3-K) activity correlates with Akt
phosphorylation and also increased matrix metalloprotein-
ase (MMP)-2 and -9 production. Matrix metalloprotein-
ases are fundamentally involved with proteolytic degra-
dation of the extracellular matrix (gelatin), a preliminary
step in the invasion process.6 The increased MMP-2/-9
production associated with PI3-K activity correlates with
invasion through matrigel, as demonstrated in this study.
Pharmacological inhibition of PI3-K activity by Wortman-
nin and LY294002 decreases invasion of glioma cells,
suggesting that targeting of this pathway is of potential
therapeutic importance.
Issues from this work that remain to be resolved include
the following: 1) whether observations on the C6 estab-
lished glioma cell line in rodents can be extended to hu-
man gliomas, and, particularly, gliomas in vivo. The au-
thors should continue the present investigation to examine
human tumors (both established and low passage lines) in
tissue culture and study the effects of the inhibitors in vivo
for further preclinical evaluation. 2) Does reintroduction
of PTEN expression by gene transfer techniques alone
normalize the upregulated PI3-kinase activity and hence
MMP-modulated invasion? The answer to this important
question would help to clarify whether clinical gene ther-
apy approaches to express PTEN in glioma cells that have
lost this tumor suppressor gene would result in decreased
MMP expression. The PI3-K activity may also likely be
driven by upstream activators, as in the interaction of inte-
grins with the extracellular matrix of white matter growth
factors3 (for example, scatter factor/hepatocyte growth
factor) that regulate motility and MMP production2 or oth-
er signaling cascades, such as protein kinase C (PKC).5 3)
How do PI3-kinase activation and Akt phosphorylation
lead to MMP expression? Phosphatidylinositol is the pre-
cursor of several intracellular signal transduction systems,
but we do not know whether the decreased invasiveness of
the C6 cells in this study is related to Akt-mediated sig-
nal transduction directly or indirectly through activation
of other kinases such as mitogen-activated protein kinas-
es (MAPKs). 4) Does PI3-kinase/Akt also control other
MMPs whose contribution to glioma invasiveness may be
more important than that of the gelatinases (MMP-2/-9)
(for example, membrane type 1-MMP).1,4
The authors are to be commended for the present obser-
vations that extend our knowledge of the complex inter-
play of intracellular events that result in increased inva-
sion, which pose yet another potential target for treating
these devastating tumors.
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RESPONSE: We appreciate Drs. Couldwell and Yong’s
comments regarding our paper. As they point out, much
work remains to be done to understand completely the re-
lationship underlying glioma invasion. Our paper begins
to characterize one of many pathways that are involved in
this complex tumor behavior.
Perhaps the most important criticism made by Drs.
Couldwell and Yong relates to whether our observations
on the rat C6 glioma cell line can be extended to human
gliomas. This criticism is appropriate when trying to ex-
trapolate any observation made in animals to the clinical
situation. We have therefore begun follow-up studies in
which we assess human glioma tissues obtained during
surgery by using immunohistochemistry for the colocal-
ization of phosphorylated Akt and MMPs.
Last, we agree that the ultimate goal of such studies is
the establishment of new therapeutic strategies for this
very difficult clinical problem.
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